All In Biotech

Drug Trial Radar · NCT04612751

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

155

Actual

Start

Feb 2, 2021

Primary completion

May 4, 2026

Study completion May 4, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Nov 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Advanced or Metastatic NSCLC

Interventions

  • Datopotamab deruxtecanDrug

    Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

  • DurvalumabDrug

    Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

  • CarboplatinDrug

    Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

  • AZD2936Drug

    Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

  • MEDI5752Drug

    Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

  • AZD7789Drug

    Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with DLTs; TEAEs and other safety parameters during the study.Time frame: DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)

Locations

42 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Santa Ana, California

  • Research Site

    St Louis, Missouri

  • Research Site

    Hackensack, New Jersey

  • Research Site

    Cleveland, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Hasselt, Belgium

  • Research Site

    Roeselare, Belgium

  • Research Site

    Aviano, Italy

  • Research Site

    Meldola, Italy

  • Research Site

    Orbassano, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Kōtoku, Japan

  • Research Site

    Sunto-gun, Japan

  • Research Site

    Yokohama, Japan

  • Research Site

    Gdansk, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    A Coruña, Spain

  • Research Site

    Badalona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Hsinchu, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan, Taiwan

  • Research Site

    Adana, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.